The “January – March 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)”, which is sometimes called the FDA Watch List, includes an item about all vascular endothelial growth factor inhibitors medicines, i.e., the VEGF inhibitors class of drugs. As regards those VEGF … [Read more...]
Leukemia Drug Iclusig Had More Safety Warnings Added In November 2016
Here is overview of this rather significant and substantial November 2016 Iclusig Prescribing Information revision which was mandated by the FDA. In the Boxed Warning section of the Iclusig drug label there was some additional safety information put in the pre-existing parts about (1) various types of arterial occlusions and (2) heart failure. … [Read more...]
Risk of Hepatitis B Reactivation Associated With Gleevec And Iclusig
Currently available medicines in the BCR-ABL TKIs class of drugs include Gleevec and Iclusig, as well as Tasigna, Bosulif, and Sprycel. These BCR-ABL tyrosine kinase inhibitors (TKIs) are used for the treatment of specific types of blood cancers, including Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute … [Read more...]